Work

Abstract B010: Updated data from ABOYA-119: A phase 1/2a trial of ATRN-119, a novel macrocyclic ATR inhibitor, in patients with advanced solid tumors harboring DNA damage repair alterations

Year: 2025

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-25-b010

Authors: Amit Mahipal, Reva Schneider, Anthony Tolcher, Shiraj Sen, Patricia LoRusso, Fiona Simpkins, M. Adham Salkeni, Crystal Miller, David Stenehjem, Mike Carleton, Philippe Pultar, David Sommerhalder

Institutions: University Hospitals Cleveland Medical Center, Yale Cancer Center, Abramson Cancer Center, University of Pennsylvania, Aprea Therapeutics, Inc. (United States), University of Minnesota, Duluth

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7093356630

Cites:

Cited by: 1

Related to: